MAYRA BARRERA, PHARMD
Pharmacist in HERMISTON, Oregon. CMS National Plan and Provider Enumeration System profile including specialty classification, practice address, and Medicare prescribing data when reported.
What the federal data shows
MAYRA BARRERA, PHARMD filed 216 Medicare Part D claims in 2023 as a Pharmacist in HERMISTON, Oregon, prescribing 90% generic.
- 216
- Part D claims, 2023
- 90%
- generic prescribing
Every figure on this page comes straight from federal CMS records (NPPES, Medicare Part D, MIPS, Open Payments) — no proprietary rating or editorial opinion is applied.
MAYRA BARRERA, PHARMD's Medicare Part D volume vs every U.S. prescriber
Total Medicare Part D claims, 2023 — across all CMS prescribers nationally
216 49th percentile higher than 49% of 1,370,886 prescribers
Each bar is a band; taller bars hold more prescribers. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.
Source CMS Medicare Part D Prescriber Public Use File · 2023
What does the federal data show about MAYRA BARRERA, PHARMD?
Quality data not reportedPrimary specialty
Medicare Part D claims
Specialty distribution in Oregon
How Pharmacist compares to other specialties among Oregon providers
Pharmacist share within Oregon
Pharmacist is one of the more visible NUCC categories in Oregon
Each bar reflects the share of in-state providers whose primary NUCC taxonomy matches the specialty. Long tail of ~690 NUCC codes folded into "Other" to keep the comparison legible.
Specialty board-certification context
Estimated specialty board-certified rate — Pharmacist (ABMS / AOA reference)
- Est. board-certified rate
- 78%
- Pharmacist ABMS/AOA estimate
Est. board-certified rate (Pharmacist) — ABMS / AOA estimate
Verify credentials
- Verify via ABMS free public lookup
- Verify via AOA osteopathic boards
- Specialty volume Pharmacist US NPIs
Specialty board-certified rate — Pharmacist estimate
Board certification through an ABMS or AOA member board signals voluntary post-licensure examination plus Maintenance of Certification cycles. CMS does not publish a per-provider board-certification field; the figure shown is the specialty-level estimated rate from ABMS / AOA reference data.
The Merit-based Incentive Payment System (MIPS) scores providers 0–100 across four performance categories: Quality, Cost, Promoting Interoperability, and Improvement Activities, weighted under 42 CFR §414.1380. Reporting is voluntary for many small practices, so absence of a MIPS score is not a quality signal.
Board certification through an ABMS or AOA member board signals voluntary post-licensure examination plus continuous Maintenance of Certification cycles. Verify any individual provider's status through certificationmatters.org (ABMS) or osteopathic.org (AOA).
MAYRA BARRERA, PHARMD appears in the CMS NPPES registry as a Pharmacist provider holding PHARMD credentials at 589 NW 11TH ST, HERMISTON, OR, 97838, with a listed phone of (541) 567-1717. NPI 1083201693 was issued on 12/29/2020. Because NPPES data is self-reported by the provider and refreshed monthly, the address, phone, and specialty reflect what BARRERA most recently submitted to CMS rather than a vetted directory listing, which is why patients should always confirm the practice is still at this location before scheduling.
Medicare Part D records for calendar year 2023 show 216 prescription claims written by this provider, covering 91 Medicare beneficiaries and totaling roughly $10K in drug spend, split 10% brand-name and 90% generic by claim count. These figures capture only Medicare Part D — commercial insurance, Medicaid, and cash-pay prescriptions are not included, and any drug-beneficiary cell under 11 is suppressed by CMS for patient privacy.
Pharmacist is a high-volume specialty nationwide, with 290,447 enrolled providers across 56 states and an average of 135 Part D claims per prescriber, so the context for interpreting these metrics differs meaningfully from a primary-care baseline. Important: PlainDoctor is a directory of publicly available government data, not medical advice, a malpractice database, or a quality rating. Inclusion here does not imply a recommendation, and absence of complaints or sanctions on this page does not mean none exist — always verify credentials through the NPPES NPI Registry, your state medical board, and the ABMS or AOA before making healthcare decisions.
Practice Address
Provider Details
| NPI | 1083201693 |
|---|---|
| Specialty | Pharmacist |
| Credentials | PHARMD |
| Gender | Female |
| NPI Issued | 12/29/2020 |
Verify this provider's license
PlainDoctor pulls this profile from the CMS NPPES public registry. Confirm MAYRA BARRERA, PHARMD's current license status, disciplinary history, and board certifications with the Oregon Medical Board in Oregon before relying on this page for a clinical or care decision.
How we sourced this profile
Brand vs generic prescribing mix · Typical
10% brand-name claims vs 90% generic, on 216 2023 Medicare Part D claims.
The federal Medicare Part D Generic Dispensing Rate national benchmark sits near 90% generic / 10% brand for primary-care prescribers, per CMS Office of the Actuary 2024 estimates. Higher brand share is common in specialty prescribing where generic equivalents are not available.
Medicare Part D Prescribing Data
CMS Medicare Part D prescriber-level data for calendar year 2023.
Prescribing Breakdown
- 30-Day Fills
- 399
- Total Day Supply
- 11,764
- Brand vs Generic
- 10% brand / 90% generic
- Brand Drug Cost
- $6K
- Generic Drug Cost
- $2K
Patient Demographics
- Average Patient Age
- 68.3 years
- Avg HCC Risk Score
- 1.26
- Gender Split
- 52% female / 48% male
- Age Distribution
- <65: 25, 65-74: 44, 75-84: N/A, 85+: N/A
Top Prescribed Drugs (Medicare Part D)
Top drugs by claim count for calendar year 2023. Based on Medicare Part D data only.
What MAYRA BARRERA, PHARMD prescribes most
Top Medicare Part D drugs by claim count, 2023
- Lisinopril
Lisinopril
16 claims
- Metformin Hcl
Metformin Hcl
16 claims
- Atorvastatin Calcium
Atorvastatin Calcium
14 claims
- Amlodipine Besylate
Amlodipine Besylate
12 claims
| Drug | Claims |
|---|---|
| Lisinopril | 16 |
| Metformin Hcl | 16 |
| Atorvastatin Calcium | 14 |
| Amlodipine Besylate | 12 |
| Trueplus Pen Needle "Pen Needle | N/A |
| Ultra-Fine Mini Pen Needle "Pen Needle | N/A |
* Counts below 11 are suppressed by CMS for patient privacy. Generic names shown where available from CMS Part D data.
Pharmacist Overview
How MAYRA BARRERA, PHARMD fits within the Pharmacist landscape nationally.
MAYRA BARRERA, PHARMD's 216 claims are above the specialty average of 135.
Nearby Pharmacist Providers in Oregon
Other clinicians with the same primary specialty enrolled in Oregon, drawn from the same CMS NPPES roster as BARRERA.
Compare Pharmacist nationally: see state-by-state distribution →
Healthcare Guides
Learn more about finding, verifying, and understanding healthcare providers.
Explore Oregon
Frequently Asked Questions
What is MAYRA BARRERA, PHARMD's specialty? ▼
How much does MAYRA BARRERA, PHARMD prescribe under Medicare Part D? ▼
Where is MAYRA BARRERA, PHARMD located? ▼
What is MAYRA BARRERA, PHARMD's NPI number? ▼
Does MAYRA BARRERA, PHARMD prescribe more brand-name or generic drugs? ▼
How many Pharmacist providers are there in the US? ▼
What drugs does MAYRA BARRERA, PHARMD prescribe most often? ▼
Does MAYRA BARRERA, PHARMD accept Medicare? ▼
How can I verify MAYRA BARRERA, PHARMD's credentials? ▼
Data Sources
- Provider Directory
- CMS National Plan and Provider Enumeration System (NPPES), download.cms.gov/nppes, updated monthly. Contains NPI, specialty, credentials, and practice location.
- Specialty Classification
- NUCC Health Care Provider Taxonomy (nucc.org), the industry standard for classifying provider specialties in Medicare and Medicaid billing.
- Prescribing Data
- CMS Medicare Part D Prescriber Public Use File (2023). Includes claims, drug costs, beneficiaries, and opioid prescribing rates.
- Limitations
- Provider data is self-reported to CMS. Prescribing data reflects Medicare Part D only and does not include commercial insurance, Medicaid, or cash prescriptions. Claims below 11 beneficiaries are suppressed by CMS for privacy.
See our complete data methodology for details on how we collect and process government data.
Data as of April 2026 (NPPES) / 2023 (Medicare Part D). Source: Centers for Medicare & Medicaid Services (CMS).
Disclaimer: Data from CMS NPPES and Medicare Part D. PlainDoctor does not rate or rank providers. Provider information is self-reported and may not be current. Always verify information directly with the provider. About · Methodology